Approximately 30% of patients with RCC have metastases at diagnosis and 30-70% of tumors can recur after surgery. Targeted therapies such as tyrosine kinase inhibitors (TKIs) and mTOR inhibitors, and VEGF monoclonal antibodies and immune checks to prolong progression-free survival (PFS) and overall survival (OS) in patients with advanced or metastatic disease Despite the promise of immunotherapies such as point inhibitors, RCC patients eventually succumb to inevitable drug resistance.
• A lump on the side, abdomen, or lower back
• Blood in pee
• Back pain on one side
• Derived Drug Resistance
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
